About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
In 2022, the Centers for Medicare & Medicaid Services (CMS) finalized a coverage determination that severely restricts patient access to an entirely new class of therapies directed at the underlying cause of Alzheimer’s disease, even if the patient matches the criteria for the intended patient population. Let’s take a closer look at some of the barriers seniors with Alzheimer’s could face in attempting to access this class of treatments, with one such therapy already FDA-approved.
A Patient’s Journey: An Example of Accessing New Alzheimer’s Treatments Through Medicare Part B image
Resource
Medicare
A Patient’s Journey: An Example of Accessing New Alzheimer’s Treatments Through Medicare Part B
A Patient’s Journey: An Example of Accessing New Alzheimer’s Treatments Through Medicare Part B image